1453195-98-6

Basic information

• Product Name: N-[2'-ethylenebis(hydrogensuccinoyloxy)ethyl]-5-(α-hydroxy-α-2-pyridylbenzyl)-7-(α-2-pyridylbenzylidene)-5-norbornene-2,3-dicarboximide dimer
• Synonyms: N-[2'-ethylenebis(hydrogensuccinoyloxy)ethyl]-5-(α-hydroxy-α-2-pyridylbenzyl)-7-(α-2-pyridylbenzylidene)-5-norbornene-2,3-dicarboximide dimer
• CAS NO: 1453195-98-6
• Molecular Weight: 1337.45
• Mol File: 1453195-98-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-[2'-ethylenebis(hydrogensuccinoyloxy)ethyl]-5-(α-hydroxy-α-2-pyridylbenzyl)-7-(α-2-pyridylbenzylidene)-5-norbornene-2,3-dicarboximide dimer(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2'-ethylenebis(hydrogensuccinoyloxy)ethyl]-5-(α-hydroxy-α-2-pyridylbenzyl)-7-(α-2-pyridylbenzylidene)-5-norbornene-2,3-dicarboximide dimer(1453195-98-6)
• EPA Substance Registry System: N-[2'-ethylenebis(hydrogensuccinoyloxy)ethyl]-5-(α-hydroxy-α-2-pyridylbenzyl)-7-(α-2-pyridylbenzylidene)-5-norbornene-2,3-dicarboximide dimer(1453195-98-6)

Safety Data

• Hazardous Substances Data: 1453195-98-6(Hazardous Substances Data)

Upstream product

• 35415-14-6 4,4'-(ethane-1,2-diylbis(oxy))bis(4-oxobutanoic acid) 

Relevant articles and documents

Prodrugs of N-dicarboximide derivatives of the rat selective toxicant norbormide

Norbormide [5-(α-hydroxy-α-2-pyridylbenzyl)-7-(α-2- pyridylbenzylidene)-5-norbornene-2,3-dicarboximide] (NRB), an existing but infrequently used rodenticide, is known to be uniquely toxic to rats but relatively harmless to other rodents and mammals. However, one major drawback of NRB as a viable rodenticide relates to an evolutionary aversion developed by the rat leading to sub-lethal dosing due to either its unpleasant 'taste' or rapid onset of effects. A series of NRB-derived prodrugs were prepared in an effort to 'mask' this acute response. Their synthesis and biological evaluation (in vitro vasoconstrictory activity, in vitro hydrolytic and enzymatic stability and lethality/palatability in vivo) is described. Prodrug 2 displayed the most promising profile with respect to a delay in the onset of symptoms and was subsequently demonstrated to be significantly more palatable to rats. Moreover, prodrug 25 was found to be largely accepted by rats in a choice trial, resulting in high mortality.